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Abstract
An alternative method for the production of biodiesel from processed fats derived from Category 1, 2
and 3 animal by-products was assessed. The method is based on a pre-cleaning process, acidic
esterification/transesterification of tallow using 1.5% methanesulfonic acid w/w; 140°C; 5.5 bar
absolute pressure (bara); 4 h, followed by fractional distillation. The application focuses on the
capacity of the alternative method to inactivate prions. Given the limitations that biodiesel presents for
direct measurement of prion infectivity, the BIOHAZ Panel considered, based on the outcome of
previous EFSA Opinions and current expert evaluation, that a reduction of 6 log10 in detectable PrP
Sc
signal would be necessary to consider the process at least equivalent to previously approved methods
for Category 1 animal by-products. This is in addition to the inactivation achieved by the pressure
sterilisation method applied before the application of any biodiesel production method. Experimental
data were provided via ad hoc studies commissioned to quantify the reduction in detectable PrPSc in
material spiked with scrapie hamster strain 263K, as measured by western blot, for the first two steps,
with distillation assumed to provide at least an additional 3 log10 reduction, based on published data.
Despite the intrinsic methodological caveats of the detection of PrPSc in laboratory studies, the BIOHAZ
Panel considers that the alternative method, including the final fractional distillation, is capable of
achieving the required 6 log10 reduction of the strain 263K PrP
Sc signal. Therefore, the method under
assessment can be considered at least equivalent to the processing methods previously approved for
the production of biodiesel from all categories of animal by-product raw materials. It is recommended
to check the feasibility of the proposed HACCP plan by recording the main processing parameters for a
certain time period under real industrial conditions.
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Summary
On 3 July 2019, the European Food Safety Authority (EFSA) received from the Irish Competent
Authority (Department of Agriculture, Food and the Marine) the application (mandate and technical
dossier) (EFSA-Q-2019-00432) under Regulation (EC) No 1069/2009 and Regulation (EU) No 142/2011
referring to the evaluation of an alternative method for production of biodiesel from processed fats
derived from Category 1, 2 and 3 animal by-products, submitted by College Proteins (hereinafter
referred to as the applicant).
The proposed new method, which would be applied after treatment of the feedstock using
processing Method 1 (pressure sterilisation), involves three key parts: (i) a pre-cleaning process for the
removal of insoluble impurities in excess of 0.15% w/w. These cleaned liquids will then be pumped to
the biodiesel tank farm where they are stored, as biodiesel feedstocks, until processing; (ii) an acidic
esterification/transesterification (1.5% methanesulfonic acid (MSA) w/w; 140°C; 5.5 bar absolute
pressure (bara); 4 h) for conversion of the cleaned feedstock into biodiesel; and (iii) fractional
distillation: the biodiesel is fractionated (≥ 220°C; 10–35 milibara (mbara)) into multiple refined
products, each containing carbon chains of a particular length, resulting in batches of biodiesel with
differing specifications.
The material to be treated is tallow produced from Category 1, 2 and 3 animal by-products plus
raw material other than animal by-products. Given the high resistance of prions to destruction and
their high thermostability, the BIOHAZ Panel agreed with the approach used by the applicant of
focusing on the capacity of the alternative method to inactivate transmissible spongiform
encephalopathies (TSE) agents.
The applicant included in the dossier the output of a quantitative risk assessment of the residual
bovine spongiform encephalopathy (BSE) risk in the treated material after the application of the
proposed alternative method, taking into account both current disease prevalence and the pre-testing
of material contributing to the feedstock. The BIOHAZ Panel considers this to be outside the remit of
the assessment of the alternative method as EFSA is only required to assess if the proposed method is
at least equivalent (in terms of hazard reduction), for the relevant categories of animal by-products, to
the processing methods laid down pursuant to point (b) of the first subparagraph of Article 15(1) of
Regulation 1069/2009.
Two independent studies were carried out on behalf of the applicant: one on the reduction of
detectable PrPSc due to acid-catalysed esterification and transesterification only, and the second on the
removal of PrPSc due to the pre-cleaning phase together with the reduction of detectable PrPSc
following acid-catalysed esterification and transesterification.
Inactivation studies based on experimentally derived laboratory TSE strains, such as the hamster-
adapted scrapie strain 263K, and the use of Western blotting (WB) to assess the presence of
detectable PrPSc following treatment, have been used in previous inactivation studies and have been
considered acceptable in several EFSA Opinions (EFSA BIOHAZ Panel, 2015, EFSA BIOHAZ Panel,
2017) to qualify the safety of renewable fuels. This methodology is increasingly being considered
suboptimal for predicting the resistance of natural TSE when they are subjected to such inactivating
protocols, due to the limited analytical sensitivity and biological relevance of WB for the detection of
prion infectivity. However, the experimental approach followed by the applicant is considered
acceptable.
The prion reduction factor claimed by the applicant for the pre-cleaning/acid esterification and
transesterification steps combined was on average ≥ 4.28 log10, with the fractional distillation assumed
to result in at least an additional 3 log10 reduction, based on published data. This is considered to be a
realistic assessment of the overall achievable reduction factor of the evaluated method at industrial
level as it avoids the need for any assumption of the additive impact of the individual pre-cleaning and
acidic esterification and transesterification steps, for which individual data sets were also provided.
Despite the inherent methodological caveats, the BIOHAZ Panel considers that the alternative
method, including the final distillation, is capable of achieving the 6 log10 reduction factor as required.
Therefore, the method under assessment can be considered at least equivalent to the processing
methods previously approved for the production of biodiesel from all categories of animal by-products
(ABP) raw materials.
The applicant provided a detailed theoretical Hazard Analysis and Critical Control Point (HACCP)
scheme that has not been verified in a full industrial-scale plant. The CCPs designated in the HACCP
plan are correctly addressed and the corrective actions proposed are appropriate. They cover the main
hazardous events that could alter the risk of exposure to any prions that may be present. However,
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since no full-scale equipment has been built so far, it is not possible to conclude on the feasibility of
the given HACCP plan in a full-scale plant, where records of the main parameters (e.g. time, pH,
temperature) should be assessed for a certain period under real operating conditions.
The applicant provided a detailed description of the risks associated with the interdependent
processes and of the procedures that would be implemented for dealing with these risks. The end
product of the proposed alternative method is biodiesel. Considering the nature and foreseen uses of
this final product, exposure of animals or humans to prions resulting from the interdependent
processes and the intended end use of the product is not expected
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1. Introduction
1.1. Background
On 3 July 2019, the European Food Safety Authority (EFSA) received from the Irish Competent
Authority (Department of Agriculture, Food and the Marine) the application (mandate and technical
dossier) (EFSA-Q-2019–00432) under Regulation (EC) No 1069/20091 and Commission Regulation (EU)
No 142/20112 referring to the evaluation of an alternative method for production of biodiesel from
processed fats derived from Category 1, 2 and 3 animal by-products (ABP), submitted by College
Proteins (hereinafter referred to as the applicant).
The applicant submitted an application as suggested in the procedure for authorisation of an
alternative method of use or disposal of ABP or derived products, laid down in Article 20 of the
Regulation (EC) No 1069/2009.
During the completeness check, performed according to Regulation (EC) No 1069/2009, it was
noticed that some information was missing or incomplete. Therefore, the dossier could not be
considered complete. On 14 August 2019, EFSA sent a letter to the applicant with three requests:
1) The applicant provided only one reference. The applicant was requested to send all the
cited references as separate pdf format files. References should be provided in a dedicated
folder ‘References’.
2) Confidential information: The applicant was requested to highlight which information should
be considered confidential (in the text, in a report) and to fill in a table in attachment.
Evidence has to be provided for each piece of information claimed confidential.
3) According to Article 20 of Regulation (EC) 1069/2009, EFSA shall receive from the Member
State Competent Authority an evaluation report and the technical dossier submitted by the
applicant. The evaluation report from the Member State was missing and the applicant was
requested to submit it. EFSA also requested it from the Member State.
On 17 September 2019, the EFSA received the missing information on the application EFSA-Q-
2019–00432, following its request dated 14 August 2019. After checking the content of the full dossier,
EFSA considered that the application EFSA-Q-2019–00432 was valid on 8 October 2019. According to
Regulation (EC) No 1069/2009, EFSA shall respect the deadline of 6 months to deliver a scientific
opinion. Therefore, the scientific opinion must be delivered by 8 April 2020.
This application presents a new method for biodiesel production. Raw materials include ABP
Category 1, 2 and 3 tallow, used cooking oil and fats, oils and greases. Additional feedstocks intended
for use and that are not subject to EFSA approval include, but are not limited to, vegetable oils, edible
oils and fatty acid distillates produced during the refinement of these oils.
According to Section 2.D, Chapter IV, Annex IV of Commission Regulation (EU) 142/2011, biodiesel
production shall be carried out according to the following processing standards:
a) Unless fish oil or rendered fat are used which have been produced in accordance with
Sections VIII or XII of Annex III to Regulation (EC) No 853/20043, respectively, the fat
fraction derived from ABP must be first processed using:
i) for Category 1 or 2 materials, processing Method 1 (pressure sterilisation) as set out in
Chapter III;
ii) for Category 3 materials, any of the processing methods 1–5 or processing method 7 or,
for material derived from fish, processing methods 1–7 as set out in Chapter III.
b) The processed fat must then be processed further using one of the following methods:
i) a process in which the processed fat must be separated from the protein and for fat
from ruminant origin, insoluble impurities in excess of 0.15% by weight must be
1 Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health rules as
regards animal by-products and derived products not intended for human consumption and repealing Regulation (EC)
No 1774/2002. OJ L 300, 14.11.2009, p. 1.
2 Commission Regulation (EU) No 142/2011 of 25 February 2011 implementing Regulation (EC) No 1069/2009 of the European
Parliament and of the Council laying down health rules as regards animal by-products and derived products not intended for
human consumption and implementing Council Directive 97/78/EC as regards certain samples and items exempt from
veterinary checks at the border under that Directive. OJ L 54, 26.2.2011, p. 1.
3 Regulation (EC) No 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down specific hygiene
rules for food of animal origin. OJ L 139, 30.4.2004, p. 55.
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removed, and the processed fat must be subsequently submitted to esterification and
transesterification.
However, esterification is not required for processed fat derived from Category 3
material. For esterification, the pH must be reduced to less than 1 by adding sulfuric
acid (H2SO4) or an equivalent acid and the mixture must be heated to 72°C for at least
2 h during which it must be intensely mixed.
Transesterification must be carried out by increasing the pH to about 14 with potassium
hydroxide or with an equivalent base at 35–50°C for at least 15 min. Transesterification
shall be carried out twice under the conditions described in this point using a new base
solution. This process must be followed by refinement of the products, including vacuum
distillation at 150°C, leading to biodiesel.
ii) a process using equivalent process parameters authorised by the competent authority.
The proposed new method, which will be applied after treatment of the feedstock using processing
Method 1 (pressure sterilisation), involves three key parts:
1) Pre-cleaning: A pre-cleaning process for the removal of insoluble impurities in excess of
0.15% w/w will occur. These cleaned liquids will then be pumped to the biodiesel tank farm
where they will be stored, as biodiesel feedstocks, until processing.
2) Acidic esterification/transesterification: The feedstocks will undergo an acidic esterification
and transesterification process (1.5% methanesulfonic acid (MSA) w/w; 140°C; 5.5 bara; 4
h) for conversion into biodiesel.
3) Fractional distillation: The biodiesel will be fractionated (≥ 220°C; 10–35 mbara) resulting in
multiple refined products each containing carbon chains of a particular length. This results in
batches of biodiesel with differing specifications.
As set out in Article 20 of Regulation (EC) No 1069/2009, EFSA is required to assess whether the
method submitted ensures that any risks to public or animal health are reduced to a degree that is at
least equivalent to that achieved by the processing methods that have already been approved for the
same category of ABP.
2. Data and methodologies
2.1. Data
The data used in the assessment were provided by the applicant as requested in Annex VII of
Commission Regulation (EU) No 142/2011 and its amendment by Commission Regulation (EU) No 749/
20114. A process flow diagram and a HACCP plan were included in the application dossier as well as a
description of risk reduction studies carried out on behalf of the applicant. The report submitted by the
Competent Authority (CA) related to the application was also considered. Relevant scientific papers
provided by experts of the Working Group (WG) were also considered during the assessment.
2.2. Methodologies
The EFSA Panel on Biological Hazards (BIOHAZ) evaluated the application for a new alternative
biodiesel production process by individually assessing the following steps as set out in the ‘EFSA
Scientific Opinion on the format for applications for new alternative methods for ABP’ (EFSA BIOHAZ
Panel, 2010). These steps are:
i) full description of the process;
ii) full description of the material to be treated;
iii) hazard identification;
iv) level of risk reduction;
v) HACCP plan;
vi) risks associated with interdependent processes;
vii) risks associated with the intended end use of the product.
4 Commission Regulation (EU) No 749/2011 of 29 July 2011 amending Regulation (EU) No 142/2011 implementing Regulation
(EC) No 1069/2009 of the European Parliament and of the Council laying down health rules as regards animal by-products and
derived products not intended for human consumption and implementing Council Directive 97/78/EC as regards certain
samples and items exempt from veterinary checks at the border under that Directive Text with EEA relevance.
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The applicant is required to document as fully as possible the different aspects of each of these
steps and, according to the CA, the application meets the requirements as laid down in the above-
mentioned EFSA Opinion.
As set out in Article 20 of European Union Regulation (EC) No 1069/2009, EFSA is required to
assess whether the method submitted ensures that the risks to public or animal health are:
a) ‘controlled in a manner which prevents their proliferation before disposal in accordance with
this Regulation or the implementing measures thereof’; or
b) ‘reduced to a degree which is at least equivalent, for the relevant categories of animal by-
products, to the processing methods laid down pursuant to point (b) of the first
subparagraph of Article 15(1)’.
This requirement for applications is described in the Commission Regulation (EU) No 142/2011
implementing Regulation (EC) No 1069/2009 and amended by Commission Regulation (EU) No 749/
2011. According to point 2(d), Chapter II, Annex VII of Commission Regulation (EU) No 142/2011, any
application for the evaluation of alternative methods shall:
‘show that the most resistant biological hazards associated with the category of materials to be
processed are reduced in any products generated during the process, including the waste water, at
least to the degree achieved by the processing standards laid down in this Regulation for the same
category of animal by-products. The degree of risk reduction must be determined with validated
direct measurements, unless modelling or comparisons with other processes are acceptable’.
The validation requirements are further described on in the 2010 EFSA Opinion. According to the
Opinion and to Chapter II, Annex VII of Commission Regulation (EU) No 142/2011 (point 3), validated
direct measurements as referred to above shall mean:
i) ‘measuring the reduction of viability/infectivity of endogenous indicator organisms during the
process, where the indicator is:
a) consistently present in the raw material in high numbers,
b) not less resistant to the lethal aspects of the treatment process, but also not
significantly more resistant, than the pathogens for which it is being used to monitor,
c) relatively easy to quantify and relatively easy to identify and to confirm;
ii) using a well-characterised test organism or virus introduced in a suitable test body into the
starting material.’
The Opinion states that:
‘results should be accompanied by evidence’. Such evidence ‘includes, for measurements,
information on the methodology used, nature of samples that have been analysed and evidence
that samples are representative (e.g. number of samples, number of tests performed and selection
of measuring points). If several treatment steps are involved, an assessment should be performed
on the degree to which individual titre reduction steps are additive, or whether early steps in the
process may compromise the efficacy of subsequent steps. In any case it is necessary to provide
the sensitivity and specificity of the detection methods applied. Data on the repeatability and
statistical variability of the measures obtained during the experiments should also be presented.’
It states also that:
‘Generally, the level of risk reduction for human and animal health which can be achieved by the
process should be evaluated on the basis of direct measurements (validation).’
Should:
‘no direct measurements of the risk reduction be available (i.e. no validation as defined above is
feasible), modelling or comparison with other processes may be acceptable if:
i) the factors leading to the risk reduction are well known;
ii) the model of risk reduction is well established; and
iii) continuous direct measurements of the factors leading to the risk reduction are provided for
the full-scale process which demonstrate that these factors are homogeneously applied
throughout the treated batch.’
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The risk reduction achieved as a result of the standard processing methods of Category 1, 2 and 3
ABP materials, as described in the Regulation, is not specified. So, there are no definitive specific risk
reduction standards for proposed alternative methods for biodiesel production using ABP. However, in a
previous EFSA Opinion (EFSA BIOHAZ Panel, 2017) dealing with proposed alternative processing
methods for Category 1 ABP, the BIOHAZ Panel decided that a reduction of 6 log10 in prion infectivity
by the alternative method is required to consider it at least equivalent, for Category 1 ABP, to the
processing methods laid down in the legislation. This is in addition to the inactivation achieved by the
pressure sterilisation method (Method 1) before the application of the alternative method. The BIOHAZ
Panel decided to use the same standard in the evaluation of the current application.
3. Assessment
3.1. The alternative method as proposed by the applicant
The description presented in this chapter has been extracted verbatim from the application, with
some editorial changes to summarise the technical procedures.
The alternative method consists of three main steps:
Step One: Raw materials that have already been treated according to Method 1 will undergo a
cleaning process for the removal of solids, particulates and phospholipids. The raw materials will then
be pumped to the biodiesel tank farm where they will be stored, as biodiesel feedstocks, until
processing.
Step Two: Cleaned feedstocks will undergo an acidic esterification and transesterification process
for complete conversion into biodiesel.
Step Three: The final step in the biodiesel production process is fractional distillation, which
separates the biodiesel product into fractions containing defined length carbon chains. This results in
batches of biodiesel with differing specifications.
3.1.1. Mandatory preliminary treatment
According to point D, Section 2, Chapter IV, Annex IV of Regulation 142/2011 as amended, a fat
fraction derived from ABP of all categories may be used for the production of biodiesel. Category 1 or
Category 2 materials must be first processed using processing Method 1 (pressure sterilisation) as set
out in Chapter III of the same Annex.
According to the application, all Category 1, 2 and 3 materials either produced by College Proteins
or another rendering company, or collected from the hospitality sector, will be sterilised according to
Method 1 (20 min, 133°C, 3 bara).
The raw material (Category 1, 2 and/or 3) is pumped into the steriliser. Pressure is increased to 3
bara. Temperature is increased to 133°C. Temperature and pressure are maintained for a retention
time of 22 min without interruption. After that, pressure is reduced to atmospheric pressure. Sterilised
raw material is discharged to a designated feedstock storage tank in the biodiesel tank farm.
3.1.2. Step one: pre-cleaning process
According to the application, the sterilised raw material and bentonite are mixed using an agitator
as the first step in the process of precipitating solids so the resulting oil has less than 0.15% w/w solid
impurities. The mixture is then pumped to the tricanter feed tank where it is split into three phases:
solids (including bentonite), water and oil. The oil fraction is pumped into a separator where the
addition of water and phosphoric acid occurs. The separator again separates the material into three
components: solids (including phospholipids), water and clean oil. This clean oil is the raw material for
the esterification and transesterification stage of the process. A flow chart of the sterilisation and pre-
cleaning process is provided in Figure A.1 of Appendix A.
3.1.3. Step two: acidic esterification and transesterification
The esterification of fatty acids and the transesterification of triglycerides with methanol are carried
out according to the reaction equations listed below. This is an acid-catalysed equilibrium reaction.
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Esterification: fatty acidþmethanol
Hþ
Fatty acids methyl ester (FAME)þ water:
Transesterification: triglyceridesþ 3 methanol
Hþ
3 Fatty acid methyl ester (FAME)þ glycerine:
The following is a reduced summary of the process steps as described in the application: (see
Figure 1)
1) The feedstock is fed into two batch reactor vessels where it is pre-heated.
2) The catalyst (MSA 99%; 1.5% w/w) and methanol (≥ 3%) are added to the reactor vessels.
3) A circulation pump re-circulates and mixes the contents of the tank.
4) The esterification/transesterification reaction is carried out at a minimum temperature of
140°C and an operating pressure in the reactor of minimum 5.5 bara with a minimum
retention time of 4 h.
5) Excess methanol (and the water created by the reaction) are continuously removed. The
methanol and water are separated using condensation, and the recovered methanol is
added back into the reaction.
6) The crude ester is then pumped out of the reactors into the settlement tanks after a
minimum residence time of 4 h.
7) Biodiesel and the glycerol/water mix are pumped out of the settlement tanks, from where
the biodiesel (FAME) is sent for further processing in the fractional distillation system into
various C-fractions (determined by the length of their carbon chains) and the glycerol/water
mix is pumped to the tank farm before being transported off-site as a by-product.
3.1.4. Step three: FAME fractional distillation
The following is a reduced summary of the process steps as described in the application (see
Figure 1):
1) The FAME mixture is pumped over a preheater and dryer into the C16 fractionation column
to obtain 16C-FAME molecules.
2) The system operates at a vacuum of lower than 35 mbara and a temperature in the
circulating sump product of ≥ 220°C. Re-distillation is required to effectively separate the
C16 and C18 FAME.
3) The distillate, which is enriched mainly with C16 FAME and contains a maximum of 10%
C18 FAME, is pumped directly to designated C16 biodiesel product tanks in the tank farm.
4) The FAME, enriched with C18, is discharged from the C16 fractionation column and fed to
the C18 distillation column. The system operates at a vacuum of lower than 30 mbara and a
temperature in the circulating sump product of ≥ 220°C.
5) The ascending FAME vapours pass through a structured packing to reach the main
condenser. The FAME vapours are condensed in the C18 condenser and collected in a
storage tank.
6) The C18 fractionation column output is transferred to a third column for increasing the yield
of the process and pumped directly to C18 biodiesel product tanks.
7) The non-distillable components [bio-heating oil (BHO)] are collected from the tank bottom
and sent to the tank farm.
Table 1 shows the comparison of the processing parameters proposed in the alternative method
with those included in the legislation.
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Figure 1: Acid-only esterification and transesterification process for the production of biodiesel as in
the application
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Table 1: Comparison of processing parameters of the alternative method and the approved in the legislation
Regulation (EU)142/2001 – Chapter IV, Section 2 D Application
Process pH Temperature Pressure Time
Final
product
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3.2. Material to be treated
3.2.1. Material to be treated as described by the applicant
Tallow is produced from the heating, filtration and sterilising of Category 1, 2 and 3 ABP in
compliance with Regulation (EU) No 1069/2009.
The following is a description of the material to be treated as described in the application.
3.2.1.1. Tallow derived from Category 1 material
Category 1 tallow is produced from animals or ABP presenting a TSE risk, including specified risk
material. This material includes ABP presenting a TSE risk or unknown risk, or a risk related to
treatment with illegal substances or to environmental contaminants. Intake material can include whole
animals or parts of animals. This material is high risk. Please see Category 1 tallow specifications in
Table 2 below.
3.2.1.2. Tallow derived from Category 3 material
Category 3 tallow includes material which was previously found ‘fit for human consumption’,
including catering waste, raw meat and fish, hides and skins; parts of slaughtered animals which are
fit for human consumption but which are not intended for human consumption for commercial
reasons, or due to problems of manufacturing or packaging defects; ABP derived from the processing
of products intended for human consumption (e.g. degreased bones and greaves); and blood from
healthy ruminants.
3.2.1.3. Used cooking oil (UCO)
Used cooking oil (UCO) is vegetable/seed/animal oil that has been used to cook foodstuff for
human consumption. Article 1 point 22 of Commission Regulation (EC) No. 142/2011 describes UCO as
catering waste and classifies it as a Category 3 waste product. Since this raw material is used to cook
meat for human consumption, the exposure of humans to prions is not expected.
UCO imported from a non-member country regulated in accordance with Commission Regulation
(EU) No 142/2011 (Annex XIV, Chapter 1) must be sourced from one of the countries on the
‘Approved List’ in Annex II of Commission Regulation (EU) No 206/20105.
3.2.1.4. Raw materials other than animal by-products
All fatty acid distillates (FAD) produced as by-products, wastes or residues during the refinement of
vegetable and seed oils are suitable for conversion to biodiesel using the acidic esterification and
transesterification process. Palm FAD, for example, is a processing residue from the refining of food-
grade palm oil for use in the food industry. Additionally, fresh, virgin cooking oils themselves are viable
options as raw materials for the process. Virgin cooking oils include vegetable and seed oils extracted
from seeds or plants. The same as animal fats, they are a mixture of triglycerides. Potential candidates
include rapeseed oil, sunflower oil, soybean oil and vegetable oil.
Table 2: Specifications of tallow
Parameter Critical control limit
Free fatty acids(a) < 25%
Insoluble impurities < 0.15%
Polyethylene < 200 ppm
Moisture < 1%
Glycerol triheptanoate (GTH) 250 ppm
(a): The free fatty acid (FFA) and insoluble impurity critical control limits listed are specific to Category 1 tallow produced by the
applicant. The polyethylene and moisture levels are dictated by the customer and the GTH levels are dictated by the
Department of Agriculture, Food and the Marine of Ireland.
5 Commission Regulation (EU) No 206/2010 of 12 March 2010 laying down lists of third countries, territories or parts thereof
authorised for the introduction into the European Union of certain animals and fresh meat and the veterinary certification
requirements.
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3.2.2. BIOHAZ Panel assessment of the material to be treated
The materials intended to be used for the production of biodiesel using the proposed alternative
method are described in detail by the applicant. Category 1 ABP tallow, pre-treated according to
Method 1, with a maximum level of insoluble impurities of 0.15%, is the highest risk material used,
due to the possible presence of the abnormal prion protein, PrPSc. Other ABP materials used as
feedstock are Category 3 ABP tallow and UCO. In addition, other non-ABP raw materials, such as by-
products from the refinement of vegetable and seed oils, are also used.
3.3. Hazard identification
3.3.1. Hazard identification as provided by the applicant
According to the application, the highest level of risk is associated with use of raw materials derived
from Category 1 ABP. The key hazard associated with this category of raw materials is the abnormal
prion protein, PrPSc and the associated risk of transmission of TSE. Category 1 material can contain
bacterial spores and viruses but as the process is considered suitable for the inactivation of prions, all
other microorganisms are believed to be inactivated in line with the reasoning presented in the EFSA
Scientific Opinion of 2017 (EFSA BIOHAZ Panel, 2017).
3.3.2. BIOHAZ Panel assessment of the hazard identification
The method proposed by the applicant is suitable for all categories of animal fats to be used as
feedstock. Category 1 material can contain various prion strains known to cause classical and atypical
forms of both bovine spongiform encephalopathy (BSE) and scrapie. Category 1 material can also
contain a wide range of other biological hazards (including some highly heat-resistant bacterial spores
and viruses). A wide range of bacterial, viral, parasitic, protozoan and fungal pathogens can also be
found in Category 2 and Category 3 materials. Given their high resistance to destruction, and, in
particular, the high thermostability of prions (Somerville et al., 2009), it is assumed that if the
alternative method ensures the inactivation of the prions, then all microorganisms, including spore-
forming bacteria and thermo-resistant viruses, will be completely inactivated. Therefore, the BIOHAZ
Panel agrees with the approach used by the applicant of focusing on the capacity of the alternative
method to reduce the risk associated with prions.
3.4. Level of risk reduction
3.4.1. Level of risk reduction as provided by the applicant
Two independent studies were carried out on behalf of the applicant: (1) Reduction of PrPSc signal
due to acid-catalysed esterification and transesterification (study 1); and (2) Reduction of PrPSc signal
due to the combined effects of pre-cleaning and acid-catalysed esterification and transesterification
(study 2). The description presented in the current section has been extracted verbatim from the
application with minor editorial changes for clarity purposes.
To obtain indicative data on the clearance of prions by the pre-cleaning process, the applicant
commissioned a laboratory-scale facsimile experiment of the industrial pre-cleaning process, as well as
an evaluation of the acid esterification and transesterification process itself, using hamster 263 K prions
and WB of prion protein as a surrogate for infectivity measurements (circumventing animal bioethics
objections and toxicity issues).
According to the results of the studies, the acidic esterification and transesterification process alone
demonstrated a reduction factor of ≥ 3.58 log10 of the abnormal protein, PrP
Sc (Table 3). The applicant
argued that the results of the two independent studies, in part contribute towards addressing the
query on the degree to which individual titre reduction steps are additive. In Table 4, it can be seen
that the pre-cleaning process alone results in a ≥ 2.98 log10 reduction in abnormal prion protein,
whereas the acidic esterification and transesterification process alone results in a reduction factor of ≥
3.58 log10. In Table 4, it is shown that when the entire process is evaluated with a prion spiked into
the tallow before pre-cleaning and a final titre is calculated for the biodiesel post-acidic esterification
and transesterification, an overall reduction factor for the entire process of ≥ 4.28 log10 (average) is
achieved. This demonstrates that the addition of the second processing step does result in an additive
effect and a further lowering of the abnormal prion protein level.
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The applicant concluded that these investigations and conclusions are limited by the dynamic range
of the assay with the ‘≥’ symbol indicating that the analysis has reached the limit of quantitation of the
assay. Therefore, it is not possible to conclude definitively if the two process steps are entirely
additive. It is important to note, however, that the individual titre reduction steps are three
independent physicochemical mechanisms: (1) phase separation (adsorption to bentonite and
distillation); (2) chemical treatment (acidification); and (3) heat (140°C reflux).
In each study, the experiment (facsimile of the industrial process) was conducted twice on two
separate days. The facsimile experiments also provided information in relation to the level of prion
clearance observed in the glycerol phase of the end product. In Table 3, according to the applicant, it
can be seen that the acidic esterification and transesterification process reduces the risk associated
with the glycerol produced during the biodiesel process. An average reduction factor of ≥ 4.45 log10
was achieved for the glycerol sample at 4 h retention time.
The applicant quoted the previous EFSA BIOHAZ Panel (2017), on the reduction factor achieved by
fractional distillation, representing the last step of the process:
‘The distillation of biodiesel under vacuum at 150°C is already part of the approved biodiesel
production process according to Commission Regulation (EU) No. 142/2011 Chapter IV Section 2.
According to the applicant, Mittelbach et al. (2007) showed that such distillation has a reduction
factor of at least 103 (3 log10) for TSE infectivity. As proteins are not volatile under the conditions of
distillation, it was assumed that they remained in the distillation residue. Mittelbach et al. (2007)
found no traces of prion protein in either the distilled samples or in the distillation residue.
Therefore, the reported effect on the level of risk reduction was considered realistic’.
On the basis of the conclusion in the 2017 EFSA Opinion that a reduction of 3 log10 for the
fractional distillation step of the applicant process is realistic, the applicant has used this reduction
factor for the fractional distillation step of the process under review.
3.4.2. BIOHAZ Panel assessment of the level of risk reduction
3.4.2.1. Assessment of the residual BSE quantitative risk assessment (QRA)
Apart from the experimental studies described above, the applicant included in the dossier the
output of a quantitative risk assessment (QRA) of the residual BSE risk in the treated material after
applying the proposed alternative method.
When dealing with the factors relevant to the QRA of the hazard in the process feedstock, a direct
reference has been made to the recent update of the EFSA QRA of the BSE risk posed by processed
animal proteins (EFSA BIOHAZ Panel, 2018). Based on that, the applicant presented an estimate of
worst-case residual risk in biodiesel after its production through the acid-only esterification and
transesterification process. In the application, the following input factors are considered in the QRA:
estimates of the prevalence of BSE in the source herds, the amount of prion protein in each animal,
the number of animals in each batch of tallow feedstock and the level of inactivation of bovine prions
achieved by the processing.
Table 3: Reduction factors of the abnormal prion protein PrPSc for study 1
Reduction factors [log10] Run 1 Run 2
Reduction factor of combined glycerol and biodiesel after 2 h of transesterification vs. spiked
starting material (SSM)
≥ 3.38 ≥ 3.38
Reduction factor of glycerol fraction after 4 h of transesterification vs. SSM ≥ 4.29 ≥ 4.61
Reduction factor of biodiesel fraction after 4 h of transesterification vs. SSM ≥ 3.59 ≥ 3.58
Table 4: Reduction factors of the abnormal prion protein PrPSc for study 2
Reduction factors [log10] Run 1 Run 2
Reduction factor of supernatant after phosphoric acid precipitation vs SSM ≥ 2.98 ≥ 2.98
Reduction factor of combined glycerol and biodiesel after 4 h of esterification/
transesterification vs. SSM
≥ 3.27 ≥ 3.20
Reduction factor of biodiesel fraction after 4 h of esterification/transesterification vs. SSM ≥ 4.32 ≥ 4.25
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In the context of this assessment, the reference to the prevalence of BSE within the total amount
of rendered material is not relevant. As explained by the applicant, in the worst-case scenario, the
probability of a clinical case of BSE in a batch (obtained by applying the hypothetical detection limit of
the passive surveillance to the size of the batch per rendering run) is not used as an input for the
subsequent steps. The assessment starts with the main assumption of the inclusion of at least one
infected cow in a batch size of 400 cattle, and the population prevalence is disregarded. The same
initial assumption is also made when a ‘more likely’ scenario was compared with the ‘worst-case’
scenario. So, the shift from the ‘worst’ to ‘more likely’ case scenario is not based on a different
prevalence scenario but on a different and more realistic partition (100 times less) of the infectivity in
tallow.
As the required focus of this assessment is to evaluate whether the public and animal health risks
are reduced to a degree which is at least equivalent, for the relevant categories of ABP, to the
approved methods, it is not relevant to consider the initial probability of a clinical case in a batch and,
therefore, the QRA outputs provided by the applicant are not considered in the assessment of this
application. Instead, the assessment focuses on whether the proposed alternative process is able to
achieve the 6 log10 reduction in prion infectivity or, as a proxy, detectable PrP
Sc, required to consider it
at least equivalent, for Category 1 ABP, to the biodiesel production method laid down in the legislation.
3.4.2.2. BIOHAZ Panel assessment of the PrPsc signal reduction
Inactivation studies based on experimentally derived laboratory strains, such as the hamster-
adapted scrapie strain 263K, and with the use of WB to assess the presence of detectable PrPSc
following treatment are increasingly being considered suboptimal as predictors of the resistance of
natural TSEs when they are subjected to such inactivating protocols (see Appendix B) due to the
inherent limited analytical sensitivity and biological relevance of WB for the detection of prion
infectivity. However, similar methods have been used in previous inactivation studies and official
guidelines (EMA, 2019). The latter acknowledges that most studies, aimed at following the partition/
removal of PrPSc and/or infectivity during plasma fractionation processes, also use:
‘rodent-adapted TSE agent (263K hamster strain) brain homogenate and microsomal brain fractions
as a spike and rely on direct [PrPSc] immunodetection tools (western blot or conformation-
dependent immunoassay) to demonstrate a drop in the TSE agent content in processed fractions
and on bioassay infectivity measurements to confirm the results’.
This approach has been considered acceptable in previous EFSA Opinions (EFSA BIOHAZ Panel,
2015, 2017) to assess the safety of renewable fuels.
The prion reduction factor claimed by the application for the pre-cleaning/acid esterification and
transesterification steps combined is on average ≥ 4.28 log10. This is considered to be a realistic
assessment of the overall achievable reduction factor of the evaluated method at industrial level since
it avoids the need for any assumption of the additive impact of the individual pre-cleaning and acidic
esterification and transesterification steps.
Based on previous studies, the final process step (fractional distillation) has been assumed to have
an additional 3 log10 reduction (Mittelbach et al., 2007). In the process described in this application,
the conditions of the distillation (≥ 220°C at 30–35 mbara) are higher than those required by the
legislation (vacuum distillation at 150°C). It cannot be assumed that a more aggressive treatment
would necessarily achieve an increased reduction in infectivity. As stated in a previous EFSA opinion
(EFSA BIOHAZ Panel, 2015), there is no consistent linear relationship between increasing temperature
and decreasing PrPSc infectivity. Nevertheless, it can be expected that the proposed fractional
distillation will achieve at least the same level of reduction as reported elsewhere.
The applicant did not provide any data about the level of inactivation achieved by the
manufacturing process on the naturally occurring cattle prion strains that might be present in the raw
material entering the industrial process (i.e. C-BSE, L-BSE and H-BSE).
The methodological caveats described in Appendix B may cause an under-/overestimation of the
actual level of reduction. Despite this, the BIOHAZ Panel considers that the reduction factor
demonstrated for the pre-cleaning, and acid esterification and transesterification steps of this process,
added to the reduction expected from the final distillation step, reaches the required minimum of 6
log10 estimated to be achieved by the existing methods when assessed using similar models, although
direct extrapolation of this outcome to naturally occurring TSE agents may not be appropriate. It is
reassuring, nevertheless, that new data relating specifically to BSE strains (Chapman et al., 2020)
indicate that the reduction in infectivity achievable by Method 1 (pressure sterilisation) is greater than
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the previously reported 3 log10 by at least one log10 cycle. This provides a safety margin when
considering the overall inactivation achieved in alternative ABP processing methods where Method 1 is
requested, such as in the biodiesel production process.
3.5. HACCP plan
3.5.1. HACCP plan and CCPs, as provided by the applicant
The applicant provided a theoretical HACCP plan. The plan was in accordance with the Codex
Alimentarius General Principles of Food Hygiene and it identified the main hazards and the risks
associated with each (considering the likelihood of occurrence and the severity of the possible impact).
Specific control measures were also included which contained the interventions/steps considered to be
CCPs according to the applicant. Finally, a list of proposed verification methods and corrective actions
to be taken when monitoring indicates that CCPs are not under control were included. A summary of
the critical control points, critical limit parameters and corrective actions included in the HACCP plan
submitted by the applicant are displayed in Table 5. A flow chart showing the critical control points
identified in the HACCP plan by the applicant is displayed in Figure A.2 of Appendix A.
According to the application, all critical parameters associated with the process are measured and
controlled by purpose-specific probes and technological devices that are calibrated and serviced
according to a strict preventative maintenance schedule as dictated by the manufacturers and
described in the technical data sheets for the equipment. All steps of the production process and all
key process parameters are continuously monitored and recorded by a Programmable Logic Controller
(PLC) system. One-off measurements such as batch weight are also measured and recorded by the
PLC system. The PLC system will issue an alert if any deviation from the specified parameters is
detected and will enter stand-by mode. If specific parameters are not achieved, the batch will be
rejected and assessed either for reprocessing or disposal by incineration. The following critical control
points are included in the HACCP plan proposed by the applicant:
3.5.1.1. CCP 1: Raw Material Intake
Before the material is discharged, it undergoes a documentation check and is weighed. If it is not
possible to correctly identify a load of raw material or correctly complete the accompanying
commercial documentation, the load will be processed as Category 1 raw material.
3.5.1.2. CCP 2: Raw material steriliser
After discharge, the raw material is pumped into a holding tank. From there, it is fed to the raw
material steriliser. The temperature is increased to 133°C and the pressure to 3 bar. The temperature
and pressure must be maintained at this level for at least 22 consecutive uninterrupted minutes. The
raw material is circulated inside the vessel during sterilisation to ensure proper exposure to the
sterilisation conditions. If there is failure in the process for any reason, the steriliser will then
automatically recommence the batch from time zero.
3.5.1.3. CCP 3/4/5/6: Bentonite treatment, tricanter, phosphoric acid treatment and
separator (pre-cleaning)
The raw materials undergo a pre-cleaning process following sterilisation to convert them to
feedstocks for the biodiesel production process. All steps in the process are monitored by an
automated PLC recording and control system that will keep the process under control allowing the
parameters to be consistently achieved.
• CCP 3: In the event of a failure in the bentonite dosing system, the system is stopped,
inspected, repaired and reset to repeat the entire dosing process. In the event of agitator
failure, heating failure or a power cut, the timer will restart at 0 min.
• CCP 4: If the tricanter speed drops below 3,000 g, a warning will be issued. An investigation
will be undertaken. The reaction will proceed and if CCP7 (solids < 0.15%) is achieved, the
batch will be accepted. If the tricanter stops, the feed pump is automatically turned off and
the process is suspended until the tricanter is repaired.
• CCP 5: In the event of a failure in the phosphoric acid dosing system, the system is stopped,
inspected, repaired and reset to repeat the entire dosing process. If the temperature in the
phosphoric acid dosing system is not achieved, the system is stopped, inspected, repaired and
reset to repeat the entire phosphoric acid dosing process. If the mixing time is not achieved,
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the reaction will proceed and if CCP7 (solids < 0.15%) is achieved, the batch will be accepted.
If not, the batch will be reprocessed. In the event of a failure of the hot water flow meter, the
system is stopped, inspected, repaired and reset to repeat the entire phosphoric acid dosing
process.
• CCP 6: If the separator speed drops below 10,000 g, a warning will be issued. An
investigation will be undertaken. The reaction will proceed and if CCP7 (solids ≤ 0.15% w/w) is
achieved, the batch will be accepted. If the separator stops, the feed pump is automatically
turned off and the process is suspended until the separator is repaired.
3.5.1.4. CCP 7: Tallow testing area
This is a standard method based on ISO 663:2017 (E). Cleaned oil is sampled and tested after the
pre-cleaning process for solids content before pumping to the biodiesel tank farm for storage as a
biodiesel feedstock. No raw material will be accepted as a feedstock for biodiesel production unless
solids are ≤ 0.15% w/w. If the solids are high at the storage tanks, the material must be pumped back
to the raw material storage tanks for reprocessing.
3.5.1.5. CCP 8: FAME conversion reactor
Acidic esterification and transesterification of feedstocks at the minimum parameters of 140°C for 4
h at 5.5 bara is controlled by a PLC. Crude ester is not discharged from the reactor vessel until all the
parameters have been achieved for 4 h continuously and a satisfactory record of all parameters has
been recorded. If the reaction stops due to a power cut or critical equipment failure, or any other
reason, maintenance will be performed, and the batch will be reprocessed from zero time. If for any
other reason the batch must be rejected at this time, it will be treated as Category 1 and incinerated
in accordance with the Category 1 disposal guidelines in Chapter II, Section 2, Article 12 of Regulation
(EU) No 1069/2009.
3.5.1.6. CCP: 9 and 10 Fractionation
Crude ester is distilled through a series of three distillation columns allowing it to be purified as well
as separated into batches of biodiesel of particular carbon chain lengths and characteristics. This
occurs at high temperature under vacuum. All steps and parameters in the process are monitored by
operators on an automated PLC recording and control system. If the vacuum or temperature is lost in
the fractional distillation column, the distillation system will automatically shut down. Maintenance will
be performed, and the process will be resumed. If for any reason it is necessary to dispose of this
batch, it will be burned in a boiler in accordance with the Category 1 disposal guidelines in Chapter II,
Section 2, Article 12 of Regulation (EU) No 1069/2009.
3.5.2. BIOHAZ Panel assessment of the HACCP plan
The applicant provided a detailed theoretical HACCP plan which has not been verified under real
industrial-scale conditions. It includes a description of the steps, and two figures presenting a
schematic representation of the process. There are some differences in terminology between the text
and figures, these are:
• In the pre-cleaning process description, process step 2, it is stated that: ‘The oil will be
collected in a designated tank and will be pumped through a flow smoothing pipe to the
vertical bowl separator.’ In the figure, instead of vertical bowl separator, it is indicated as ‘disc
separator’; the same terminology should be used. Additionally, the water phase separated in
this step is not mentioned in Figure A.1 of Appendix A.
• In the hazard identification section, for biological hazards, bovine prions are the only relevant
biological hazard mentioned. Although it is justified, other hazards that may be present should
be mentioned, as well as the latest information about differences in resistance among TSE
strains. In this section, control of the different hazards according to literature data and the
production process itself are included.
The CCPs designated in the HACCP plan are correctly addressed and the corrective actions
proposed are appropriate. They cover the main hazardous events that could alter the risk of exposure
to prions.
The proposed HACCP plan can be considered satisfactory if the whole scheme is verified under full-
scale conditions.
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Table 5: Summary of the critical control points, critical limit parameters and corrective actions included in the HACCP plan submitted by the applicant






1 Raw material reception Identification, weight,
documentation
Absolute Hold material until all
correct
Daily intake sheet, Weighbridge
management system
Sign off
2 Raw material steriliser Temperature, pressure,
time










≥ 6% w/w, ≥ 30 min,
≥ 300 rpm, ≥ 98°C
Repair and repeat cycle PLC Visual, PLC contemporaneous,
Historical, Data Logger
Production manager
4 Tricanter Speed and retention time ≥ 3,000 g, ≥ 2 min Repair and repeat if
target not met







≥ 0.5% v/v, ≥ 98°C,
≥ 2 min
Repair and repeat process PLC Visual, PLC contemporaneous,
Historical, Data Logger
Production manager
6 Separator Speed 10,000 g Suspension of process
and repair
PLC Visual, PLC contemporaneous,
Historical, Data Logger
Production manager




Mass of tallow, MSA,
methanol and pressure,
temperature, time
kg, ≥ 1.5% w/w, ≥ 3%
w/w and ≥ 5.5 bara, ≥
140°C, ≥ 240 min
Process suspended,
restarted or batch might
be rejected










Pressure, temperature < 30 mbar, ≥ 220°C Repair and Repeat Cycle PLC Visual, PLC contemporaneous,
Historical, Data Logger
Production manager
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3.6. Risk associated with interdependent processes
3.6.1. Risk associated with interdependent processes as provided by the
applicant
Point 5(a), Chapter II, Annex VII of Regulation (EU) 142/2011 requires that the applicant provides
information on the risks associated with interdependent processes. In particular, the applicant is
required to provide information on the outcome of an evaluation of possible indirect impacts, which
may: (i) influence the level of risk reduction of a particular process; or (ii) arise from transport or
storage of any products generated during the process and from the safe disposal of such products,
including waste water. The description presented in the current section has been extracted verbatim
from the application, with minor editorial changes for clarity purposes.
3.6.1.1. Storage
All end products (tallow) and by-products (wastewater, solids) of the pre-cleaning process are stored in
bunded, designated tanks or processed. All end products (biodiesel and glycerine) and by-products
(wastewater, methanol water) from the acid esterification and transesterification and distillation processes
are stored in specifically designated tanks in the bunded and monitored tank farm. Any environmental risk
or risk to human or animal health due to spills or leaks during storage or filling of tankers is mitigated by
the use of bunded spaces and sumps that can be pumped back to designated storage.
3.6.1.2. Transport
All end products or by-products that are transported off-site will be hauled in designated tankers,
constructed from the appropriate corrosion-resistant materials, by licensed hauliers. Tankers will be
labelled with the appropriate signage and all loads will be accompanied by the correct legal and
environmental paperwork. If a tanker containing either biodiesel or glycerine crashed and due to some
extreme event the specialised, heavy-duty tanker was breached and biodiesel or glycerine was
discharged to the road and verge, exposure to prions from that glycerine or biodiesel would not be
expected.
3.6.1.3. Safe disposal of by-products
Solids from the pre-cleaning process
All solids removed from raw materials during the pre-cleaning process, either by the tricanter or
separator, will be transported back by a one-directional screw conveyor system into the intake pit of
the Category 1 rendering plant. There, the material will be processed in accordance with Commission
Regulation (EU) No 142/2011 and in accordance with Article 12 of Regulation (EC) No 1069/2009
under Department of Agriculture Approval No. R911.
Wastewater from the pre-cleaning process
Wastewater from the pre-cleaning process that is removed from the raw materials either by the
tricanter or separator will enter the waste heat evaporator in the Category 1 rendering plant and be
processed in accordance with Section II of Chapter 1 of Annex IV of Commission Regulation (EU) 142/
2011.
Glycerine
Glycerine that is produced as a by-product from the acidic esterification and transesterification
process may be used as a fuel source for power generation or will be disposed as a Category 1 by-
product by incineration at an appropriately licensed facility in accordance with Article 12 of Regulation
(EC) No 1069/2009.
Bio-heating oil
Bio-heating oil (BHO) collected from the tank bottoms of the fractional distillation columns will be
burned in a boiler in accordance with Article 12 of Regulation (EC) No 1069/2009.
Wastewater from the biodiesel production and methanol rectification processes
Wastewater that is produced as a by-product from the acidic esterification and transesterification
process will be processed in the wastewater treatment plant (WWTP) in accordance with Section II of
Chapter 1 of Annex IV of Commission Regulation (EU) 142/2011. All wastewater will have been
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evaporated and condensed during either the acidic esterification and transesterification or methanol
rectification process and will be free of prions since proteins are not known to evaporate. Additionally,
the methanol rectification process is dosed with NaOH to maintain a neutral range of pH 6–7.
3.6.2. BIOHAZ Panel assessment of the risk associated with interdependent
processes
The applicant provided a detailed description of the risks associated with the interdependent
processes and of the procedures that would be implemented for dealing with these risks.
The procedures on the storage and transport of ABP and derived products are in compliance with
the requirements set out in Article 21 of Regulation (EC) No 1069/2009, Article 17 and Annex VIII of
Commission Regulation (EU) No 142/2011 and various other parts of these Regulations.
The procedure for dealing with wastewater from the pre-cleaning process and from the acid-only
esterification and transesterification process is in compliance with the requirements set out for
wastewater treatment in ABP processing plants in Section 2, Chapter 1, Annex IV of Commission
Regulation (EU) No 142/2011. The procedures for dealing with other by-products of the alternative
process, including solids from the pre-cleaning process, methanol, glycerine and BHO from the acid-
only esterification and transesterification process are in compliance with Article 12 of Commission
Regulation (EC) No 1069/2009 and with Section 3, Chapter IV of Annex IV of Commission Regulation
(EU) No 142/2011. Measures to mitigate any risks that may arise from interdependent processes are
also set out in the HACCP plan accompanying the application. Considering the nature of these by-
products and the procedures for dealing with them, exposure of animals or humans to prions resulting
from/related to interdependent processes would not be expected.
3.6.3. Risk associated with the intended end use of the product
3.6.3.1. Risk associated with the intended end use of the products from the process as
provided by the applicant
The description presented in the current section has been extracted verbatim from the application
with minor editorial changes for clarity purposes.
Biodiesel will be blended with fossil diesel for use in domestic and commercial vehicles and will be
dispensed at forecourts of retail filling stations. As discussed in Mittelbach et al. (2007), a limited
number of potential routes of infection of humans with BSE exist because of the residual risk
associated with biodiesel. There are two main routes of potential infection that exist: oral and
subcutaneous. It is highly unlikely that biodiesel would be intentionally ingested and equally, prions will
not be inhaled ‘since proteins are not known to evaporate’ (Mittelbach et al., 2007). The subcutaneous
route represents a more viable potential route of exposure if the barrier created by the skin in some
way suffered a loss of integrity such as an open cut or wound. If a wound or trauma had
compromised the integrity of the skin, the volume of biodiesel that could penetrate the underlying cells
would be in the range of less than a millilitre. So, the exposure to prions via filling a vehicle with
biodiesel is not expected. If because of an explosion, leak or accidental submersion, a person became
entirely immersed in biodiesel, the exposure prions via biodiesel would be equally not expected.
The possibility of exposure of an animal either by ingesting or being exposed by the subcutaneous
route to prions in fossil diesel containing biodiesel is not expected. For this to occur, it would be
necessary for either a spillage or other major incident to happen. All areas of the biodiesel facility
where a spill or leak could occur are bunded to an appropriate capacity. The entire bottom floor of the
production facility is bunded to a level of minus 0.5 m. The loading station will be bunded and have a
sump that can be pumped back into a storage tank. The tank farm is constructed in a bund that can
hold 110% the capacity of the largest tank or 25% the capacity of the tank farm. As a result of these
bunds and sumps, it is extremely unlikely that any animal would come into contact with 100%
biodiesel. All wholesale fuel facilities would have similar environmental protection strategies and on-site
security. Additionally, due to the hazardous nature of fuel, retail filling stations are extremely unlikely to
have present exposed fuel. Therefore, the exposure of an animal to prions via contact with sufficient
biodiesel is not expected.
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3.6.4. BIOHAZ Panel assessment of the risk associated with the intended end
use of the products
The end product of the proposed alternative method is biodiesel. Considering the nature and
foreseen uses of this final product, exposure of animals or humans to prions resulting from the
intended end use is not expected.
4. Conclusions
• Since the starting material includes Category 1 tallow, the applicant considered that, of any
biological hazards that may be present, prions would be the most resistant. The BIOHAZ
Panel agrees with the approach used by the applicant of focusing on the capacity of the
alternative method to inactivate prions.
• The dossier contains a detailed theoretical HACCP plan and information about the risks of the
interdependent processes and those associated with the intended end use. The BIOHAZ
Panel considers that the measures proposed in the dossier to deal with these risks are
compliant with the relevant legislation.
• The dossier contains studies commissioned by the applicant to specifically evaluate the
detectable PrPSc reduction factor achievable by the proposed alternative method, using the
same substrate and processing parameters. Despite its inherent limitations, the experimental
approach followed is considered acceptable.
• In addition to estimates of prion reduction factors associated with the individual steps of the
processing method, the overall achievable reduction factor of the evaluated method has been
provided. This avoids the need to assume an additive impact for individual steps and offers a
more realistic assessment.
• Previous EFSA Opinions established that a reduction in prion infectivity, or detectable PrPSc, of
at least 6 log10 should be achieved to consider a method at least equivalent, for the relevant
category of ABP (Category 1), to the processing methods previously approved.
• The prion reduction factor claimed in the application for the pre-cleaning and acid esterification
and transesterification processes combined was at least 4.3 log10, as established by the
estimated titre of a 263K hamster strain spike, using WB detection of the residual PrPSc signal.
The final step (fractional distillation) is assumed to achieve at least an additional 3 log10
reduction, based on published data.
• Inactivation studies based on experimentally derived laboratory TSE strains, such as the
hamster-adapted scrapie strain 263K, and with the use of WB to assess the presence of
detectable PrPSc following treatment, are increasingly being considered suboptimal as
predictors of the resistance of natural TSE when they are subjected to such inactivating
protocols, due to the inherent limited analytical sensitivity and biological relevance of WB for
the detection of prion infectivity. Despite these methodological caveats, the BIOHAZ
Panel considers that the alternative method, including the final fractional distillation, is capable
of achieving the 6 log10 reduction factor that enables it to be considered at least equivalent to
the processing methods previously approved for the production of biodiesel from all categories
of ABP raw materials.
5. Recommendations
• To check the feasibility of the proposed HACCP plan, the records of the main processing
parameters (e.g. time, pH, temperature) should be assessed for a certain time period under
real industrial conditions.
6. Documentation as provided to EFSA
• Application for evaluation of an alternative process for production of biodiesel from rendered
fat of all categories of animal by-products. First submission. July 2019. Submitted by: College
Proteins Unlimited Company. College, Nobber, Co. Meath, A82 XT61, Ireland.
• Application for evaluation of an alternative process for production of biodiesel from rendered
fat of all categories of animal by-products. Second submission. September 2019. Submitted by:
College Proteins Unlimited Company. College, Nobber, Co. Meath, A82 XT61, Ireland.
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Glossary
Absolute pressure Pressure zero – referenced against a perfect vacuum. The standard absolute
atmosphere pressure is 101,325 Pa or 1.01325 bar (gauge pressure plus
atmospheric pressure)
It can be indicated by an ‘a’ after the pressure unit (e.g. ‘bara’)
https://www.esi-tec.com/blog-pressure-sensors-transmitter-transducer/2013/06/
difference-between-gauge-and-absolute-pressure-measurement
Bar Non-international system of units (SI unit) for pressure, accepted for use but not
encouraged. One hundred thousand pascals are called a bar (100,000 Pa = 1
bar). Commonly used for technical applications. https://www.nist.gov/pml/special-
publication-811/nist-guide-si-chapter-5-units-outside-si
Bara Absolute pressure measured in bar
Barg Gauge pressure measured in bar
Biodiesel Renewable fuel comprised of mono-alkyl esters of long chain fatty acids derived
from vegetable oils or animal fats https://www.biodiesel.org/what-is-biodiesel/biod
iesel-basics
C16 Obtained biodiesel fraction after distillation with fatty acid methyl esters derived
from fatty acids consisting of a chain of 16 carbon atoms
C18
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Obtained biodiesel fraction after distillation with fatty acid methyl esters derived
from fatty acids consisting of a chain of 18 carbon atoms
Distillation Separation of different components in a liquid by evaporation and condensation
using various boiling points of the substances to be separated
https://www.britannica.com/science/distillation
Esterification The reaction between an alcohol (R-COH) and a carboxylic acid (R’-COOH)
forming in the presence of a catalyst an ester (R-COO-R’) and water (H2O). Typical
alcohols used in esterification are methanol and ethanol. A reaction with free fatty
acids results in fatty acid alkyl esters and water
https://www.britannica.com/science/alcohol/Esterification#ref998542
FAME Fatty acid methyl ester. An ester obtained by reactions of fatty acids with
methanol
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=4986
Gauge pressure Pressure zero – referenced against the environment (ambient air pressure). The
standard gauge atmosphere pressure is 0 Pa or 0 bar (absolute pressure minus
atmospheric pressure)
Can be indicated by an ‘g’ after the pressure unit (e.g. ‘barg’)
https://physics.stackexchange.com/questions/20460/gauge-pressure-vs-absolute-
pressure
Methyl ester An ester obtained by reactions with the alcohol methanol (R-COO-CH3)
https://www.darpro-bioenergy.com/about-dar-pro-bioenergy/contact/methyl-ester-
faqs
Pascal Standard unit for pressure as defined by the International System of Units (SI
unit). It indicates the ratio of force applied per area covered (kg m1 s2)
https://www.nist.gov/pml/special-publication-811/nist-guide-si-chapter-4-two-cla
sses-si-units-and-si-prefixes
Tallow Animal fat obtained after rendering of animal by-products
https://www.daera-ni.gov.uk/articles/animal-by-products-specific-guidance
Transesterification The reaction between an alcohol (R’’-OH) and an ester (R-COO-R’) forming in the
presence of a catalyst a different ester (R-COO-R’’) and a different alcohol (R’-OH)
with exchanged R groups






BIOHAZ EFSA Panel on Biological Hazards
BSE bovine spongiform encephalopathy
CA Competent Authority
C-BSE classical bovine spongiform encephalopathy
CCP critical control point
FAD fatty acid distillates
FAME fatty acid methyl ester
GTH glycerol triheptanoate
H2SO4 sulfuric acid
HACCP hazard analysis and critical control point
H-BSE H-type bovine spongiform encephalopathy
L-BSE L-type bovine spongiform encephalopathy
MSA methanesulfonic acid
PLC programmable logic controller
PMCA protein misfolding cyclic amplification
PrPSc abnormal protease-resistant isoform of prion protein
QRA quantitative risk assessment
RT-QuIC real-time quaking-induced conversion
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SSM spiked starting material
TSE transmissible spongiform encephalopathies
UCO used cooking oil
WB western blotting
WG Working Group
WWTP wastewater treatment plant
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Appendix A – Flow charts
Figure A.1: Schematic of the sterilisation and pre-cleaning process for the removal of solids and
impurities from the biodiesel raw materials
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Figure A.2: Critical control points identified in the HACCP by the applicant
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Appendix B – Issues relating to methods for prion quantification
For TSE, the most reliable approach to determining the potential infectivity of a sample is to
bioassay it in a rodent model that is appropriate for the strain and/or host species under consideration.
However, this process requires specialist facilities and resources, and may take years to complete. In
addition, the toxic nature of some substrates, such as those involved with biodiesel production, render
this methodology inappropriate for the validation or quantification of the TSE inactivation achieved by
this process.
In the context of disease confirmation, the use of abnormal PrP immunochemical detection
methods such as immunohistochemistry and WB has become the mainstay of statutory diagnostic
procedures. So, the presence of detectable PrPSc has become widely used as a proxy for infectivity,
although it is accepted that WB is less sensitive than bioassay (EFSA BIOHAZ Panel, 2015).
Additionally, studies have demonstrated that there is no consistent or linear relationship between the
measurable amount of PrPSc and the amount of infectivity (Gonzalez et al., 2012; Marın-Moreno et al.,
2019). In a range of contexts, infectivity has been demonstrated in the absence of detectable PrPSc
(Lasmezas et al., 1997; Wells et al., 2005; Bruederle et al., 2008; Andreoletti et al., 2011; Simmons
et al., 2011; Marın-Moreno et al., 2016; Ackermann et al., 2017), and PrPSc has also been reported in
the absence of infectivity (Piccardo et al., 2013; Serra et al., 2017, 2018).
Seminal studies on prion decontamination/inactivation relied on the use of laboratory-adapted
rodent prion strains derived from naturally occurring scrapie (such as ME7, or 263K), or classical BSE
(301V) (Brown et al., 1990; Taylor, 1991, 1999). Over the last 30 years, however, it has become clear
that the strains involved in naturally occurring prion diseases (scrapie, BSE, CWD or CJD) display very
different resistance/sensitivity to decontaminating treatments (autoclaving or chemical inactivation)
(Taylor, 1986, 2000; Taylor et al., 1994).
It has also been established that even different prion strains from naturally occurring TSE in the
same host species can behave very differently. In cattle, C-BSE, H-BSE and L-BSE all have different
responses to inactivation by the ABP sterilisation ‘Method 1’ (Chapman et al., 2020); similarly, in sheep,
classical and atypical scrapie behave differently when they are subjected to Method 1 conditions
(Spiropoulos et al., 2019). So, the resistance/sensitivity of different prion strain/host combinations to
decontamination or inactivation treatments may vary substantially, and should, ideally, be
experimentally characterised for each given situation.
Over the last 20 years, in vitro amplification of prions by either protein misfolding cyclic
amplification (PMCA) (Saborio et al., 2001; Castilla et al., 2005; Kurt et al., 2007; Lacroux et al., 2012)
or real-time quaking-induced conversion (RT-QuiC) (Atarashi et al., 2011; Orru et al., 2011, 2012) have
emerged as sensitive and efficient methodologies for the detection and quantification of prions. Both
rely on the detection of PrP structural conversion and polymerisation upon addition of PrPSc ‘seeds’
contained within infected samples (for a review, see Krauss and Vorberg, 2013). The sensitivity of
detection achieved by PMCA and RT-QuiC exceeds the sensitivity of the reference bioassay models. A
relationship between seeding activity (as measured by RT-QuiC or PMCA) and infectivity (measured by
bioassay in a reference model) can be established (Makarava et al., 2012; Boerner et al., 2013; Douet
et al., 2017).
In the context of the quantification of prion reduction achieved during processes such as the
manufacturing of biodiesel, in vitro amplification methodologies such as PMCA or RT-QuiC now offer a
better experimental approach than the measurement of the PrPSc WB signal, and would enable the
testing of additional prion strains, such as BSE from cattle, that would better reflect the field situation.
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